Literature DB >> 27168873

Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after surgery: A comment for moving forward.

Jian-Hong Zhong1, Tian Yang1, Bang-De Xiang1, Le-Qun Li1, Liang Ma1.   

Abstract

Recurrence rate of hepatocellular carcinoma remains quite high even after surgery, and no postoperative therapies have been definitively shown to prevent hepatocellular carcinoma recurrence. A previous study showed that therapy with nucleos(t)ide analogues given to such patients after surgery significantly improved survival. However, many questions still exist about the usage of nucleos(t)ide analogues for patients with hepatocellular carcinoma after surgery.

Entities:  

Keywords:  Antiviral therapy; Hepatitis B virus; Hepatocellular carcinoma; Unanswered question

Year:  2016        PMID： 27168873      PMCID： PMC4858625          DOI： 10.4254/wjh.v8.i13.605

Source DB:  PubMed          Journal:  World J Hepatol


  7 in total

1.  Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation.

Authors:  Teng-Yu Lee; Jaw-Town Lin; Yi-Siou Zeng; Yi-Ju Chen; Ming-Shiang Wu; Chun-Ying Wu
Journal:  Hepatology       Date:  2015-12-18       Impact factor: 17.425

Review 2.  Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis.

Authors:  Yanming Zhou; Zhansai Zhang; Yanfang Zhao; Lupeng Wu; Bin Li
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

Review 3.  Postoperative therapy options for hepatocellular carcinoma.

Authors:  Jian-Hong Zhong; Liang Ma; Le-Qun Li
Journal:  Scand J Gastroenterol       Date:  2014-04-10       Impact factor: 2.423

4.  Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma.

Authors:  Jian-hong Zhong; Yang Ke; Wen-feng Gong; Bang-de Xiang; Liang Ma; Xin-ping Ye; Tao Peng; Gui-sheng Xie; Le-qun Li
Journal:  Ann Surg       Date:  2014-08       Impact factor: 12.969

5.  Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.

Authors:  A K Singal; H Salameh; Y-F Kuo; R J Fontana
Journal:  Aliment Pharmacol Ther       Date:  2013-05-28       Impact factor: 8.171

6.  Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.

Authors:  Gang Huang; Wan Yee Lau; Zhen-Guang Wang; Ze-Ya Pan; Sheng-Xian Yuan; Feng Shen; Wei-Ping Zhou; Meng-Chao Wu
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

7.  Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions.

Authors:  Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2014-11-28
  7 in total
  2 in total

1.  Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas.

Authors:  Yanyan Wei; Yongxiang Yi; Chen Tao; Wei Ye; Wei Zhao
Journal:  Cancer Manag Res       Date:  2019-09-17       Impact factor: 3.989

2.  Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching.

Authors:  Bao-Hong Yuan; Ru-Hong Li; Wei-Ping Yuan; Bang-De Xiang; Ming-Hua Zheng; Tian Yang; Jian-Hong Zhong; Le-Qun Li
Journal:  Oncotarget       Date:  2017-02-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.